Bourgeon Capital Management LLC Has $19.08 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Bourgeon Capital Management LLC cut its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 611,345 shares of the company’s stock after selling 108,655 shares during the quarter. Teva Pharmaceutical Industries makes up 3.1% of Bourgeon Capital Management LLC’s portfolio, making the stock its 5th largest holding. Bourgeon Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $19,080,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Menora Mivtachim Holdings LTD. boosted its position in Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after purchasing an additional 9,303,978 shares during the period. Wellington Management Group LLP grew its stake in Teva Pharmaceutical Industries by 39,228.4% during the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after buying an additional 6,878,304 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter worth $100,939,000. Maverick Capital Ltd. increased its position in Teva Pharmaceutical Industries by 14,351.6% in the second quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock worth $73,370,000 after buying an additional 4,347,398 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its stake in Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Placid Jover sold 14,150 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the sale, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $214,532.58. This represents a 67.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard Daniell sold 17,295 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares of the company’s stock, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 920,901 shares of company stock worth $30,056,789. Company insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TEVA. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Piper Sandler reissued an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $30.12 on Wednesday. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The stock’s fifty day moving average is $32.24 and its 200-day moving average is $27.61. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The firm has a market capitalization of $34.63 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 9.52 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.